Killing the Last 0.1%: Targeting Cancer Persister Cells

Cancer therapy has a persistent blind spot. Tumors shrink, biomarkers improve, scans look clean—and yet relapse remains common. The reason is often a tiny population of surviving cells known as persisters.

These cells are not genetically resistant. They are identical to the bulk tumor but enter a transient, drug-tolerant state that allows them to survive treatment. Even if they represent just one in a thousand cells, they are enough to eventually repopulate the disease.

For years, persisters were difficult to study. They are rare, unstable, and highly context-dependent, making systematic analysis nearly impossible. A new study from UCSF addresses this directly by using an automated, high-throughput platform to generate and test thousands of mini-tumors in parallel, allowing researchers to identify and functionally probe persister cells at scale.

The key finding is unexpected: persister cells are not purely heterogeneous. Across different tumor types and treatment conditions, they exhibit shared vulnerabilities. Out of 94 candidate compounds, a subset of 9 consistently impaired persister survival, suggesting these cells rely on common adaptive mechanisms.

This challenges the traditional mutation-driven model of resistance. Persisters represent a parallel pathway, survival through reversible cellular states rather than permanent genetic change. Mechanistically, this aligns with metabolic rewiring, stress response activation, and epigenetic plasticity, all of which enable cells to endure therapy without proliferating.

Clinically, this opens a critical window. After initial treatment response, when tumor burden is low, persister cells may be most exposed. Targeting them at this stage could prevent the emergence of resistant disease rather than reacting to it.

In prostate cancer, this concept is particularly relevant. Deep responses to androgen deprivation and AR-targeted therapies are common, yet durable eradication is rare. The transition toward resistant or AR-independent states may be driven, at least in part, by persister-like populations.

The implication is straightforward: eliminating the bulk tumor is not enough. The real challenge is the last fraction of cells, the ones that survive. With the ability to now identify and target their vulnerabilities, persisters shift from an abstract concept to a tractable therapeutic problem. These findings are entirely preclinical and limited to cell-based systems, but they provide a scalable framework to identify candidate vulnerabilities for in vivo testing.

Source.